Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension

Alejandro Velasco, Oliver Chung, Fayez Raza, Ambarish Pandey, Stephanie K Brinker, Debbie Arbique, Angela L Price, Yair Lotan, Sandeep R Das, Wanpen Vongpatanasin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Primary aldosteronism (PA) is present in up to 20% of patients with treatment-resistant hypertension (TRH). Investigation for PA in patients with TRH is recommended by current guidelines after medication nonadherence is excluded. Studies using therapeutic drug monitoring (TDM) have shown that >50% of patients with TRH are nonadherent to their prescribed antihypertensive medications. However, the relationship between the prevalence of PA and medication adherence as confirmed by TDM has not been previously assessed. A retrospective analysis from a hypertension referral clinic showed that prevalence of PA in adherent patients with TRH by TDM was significantly higher than in nonadherent patients (28% vs 8%, P<.05). Furthermore, cost analysis showed that TDM-guided PA screening was $590.69 less expensive per patient, with minimal impact on the diagnostic accuracy. These data support a TDM-guided PA screening approach as a cost-saving strategy compared with routine PA screening for TRH.

Original languageEnglish (US)
Pages (from-to)713-719
Number of pages7
JournalJournal of clinical hypertension
Volume17
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Hyperaldosteronism
Drug Monitoring
Cost-Benefit Analysis
Hypertension
Medication Adherence
Therapeutics
Costs and Cost Analysis
Antihypertensive Agents
Referral and Consultation
Guidelines

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension. / Velasco, Alejandro; Chung, Oliver; Raza, Fayez; Pandey, Ambarish; Brinker, Stephanie K; Arbique, Debbie; Price, Angela L; Lotan, Yair; Das, Sandeep R; Vongpatanasin, Wanpen.

In: Journal of clinical hypertension, Vol. 17, No. 9, 01.09.2015, p. 713-719.

Research output: Contribution to journalArticle

@article{44b413590b734412ac2efd9f416e4a8f,
title = "Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension",
abstract = "Primary aldosteronism (PA) is present in up to 20{\%} of patients with treatment-resistant hypertension (TRH). Investigation for PA in patients with TRH is recommended by current guidelines after medication nonadherence is excluded. Studies using therapeutic drug monitoring (TDM) have shown that >50{\%} of patients with TRH are nonadherent to their prescribed antihypertensive medications. However, the relationship between the prevalence of PA and medication adherence as confirmed by TDM has not been previously assessed. A retrospective analysis from a hypertension referral clinic showed that prevalence of PA in adherent patients with TRH by TDM was significantly higher than in nonadherent patients (28{\%} vs 8{\%}, P<.05). Furthermore, cost analysis showed that TDM-guided PA screening was $590.69 less expensive per patient, with minimal impact on the diagnostic accuracy. These data support a TDM-guided PA screening approach as a cost-saving strategy compared with routine PA screening for TRH.",
author = "Alejandro Velasco and Oliver Chung and Fayez Raza and Ambarish Pandey and Brinker, {Stephanie K} and Debbie Arbique and Price, {Angela L} and Yair Lotan and Das, {Sandeep R} and Wanpen Vongpatanasin",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/jch.12570",
language = "English (US)",
volume = "17",
pages = "713--719",
journal = "Journal of clinical hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension

AU - Velasco, Alejandro

AU - Chung, Oliver

AU - Raza, Fayez

AU - Pandey, Ambarish

AU - Brinker, Stephanie K

AU - Arbique, Debbie

AU - Price, Angela L

AU - Lotan, Yair

AU - Das, Sandeep R

AU - Vongpatanasin, Wanpen

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Primary aldosteronism (PA) is present in up to 20% of patients with treatment-resistant hypertension (TRH). Investigation for PA in patients with TRH is recommended by current guidelines after medication nonadherence is excluded. Studies using therapeutic drug monitoring (TDM) have shown that >50% of patients with TRH are nonadherent to their prescribed antihypertensive medications. However, the relationship between the prevalence of PA and medication adherence as confirmed by TDM has not been previously assessed. A retrospective analysis from a hypertension referral clinic showed that prevalence of PA in adherent patients with TRH by TDM was significantly higher than in nonadherent patients (28% vs 8%, P<.05). Furthermore, cost analysis showed that TDM-guided PA screening was $590.69 less expensive per patient, with minimal impact on the diagnostic accuracy. These data support a TDM-guided PA screening approach as a cost-saving strategy compared with routine PA screening for TRH.

AB - Primary aldosteronism (PA) is present in up to 20% of patients with treatment-resistant hypertension (TRH). Investigation for PA in patients with TRH is recommended by current guidelines after medication nonadherence is excluded. Studies using therapeutic drug monitoring (TDM) have shown that >50% of patients with TRH are nonadherent to their prescribed antihypertensive medications. However, the relationship between the prevalence of PA and medication adherence as confirmed by TDM has not been previously assessed. A retrospective analysis from a hypertension referral clinic showed that prevalence of PA in adherent patients with TRH by TDM was significantly higher than in nonadherent patients (28% vs 8%, P<.05). Furthermore, cost analysis showed that TDM-guided PA screening was $590.69 less expensive per patient, with minimal impact on the diagnostic accuracy. These data support a TDM-guided PA screening approach as a cost-saving strategy compared with routine PA screening for TRH.

UR - http://www.scopus.com/inward/record.url?scp=84940896137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940896137&partnerID=8YFLogxK

U2 - 10.1111/jch.12570

DO - 10.1111/jch.12570

M3 - Article

VL - 17

SP - 713

EP - 719

JO - Journal of clinical hypertension

JF - Journal of clinical hypertension

SN - 0895-7061

IS - 9

ER -